Orphazyme announces the completion of its seed financing with Novo Seeds joining as investor

09-03-2010

Orphazyme develops pharmaceuticals that target lysosomes. The company is dedicated to developing a novel class of therapeutics for the treatment of lysosomal storage diseases, a family of rare but debilitating disorders. Orphazyme is built on the discoveries of its scientific founders Thomas Kirkegaard Jensen and Marja Jäättela, some of which were published earlier this year in Nature.

Click here to read the press release.